WaveMan
WaveMan · Company
GH · Guardant Health, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

GH Guardant Health (GH) Insider Trading, Ownership & Congress Trades

Healthcare Services · Services-medical laboratories · CIK 0001576280
Quote by TradingView
C-suite buying · 1Congress · 1Form 144 · 14
Funds added, last quarter
365
13F, latest reported quarter
Conversions, 180 days
103
Codes C/M, not in net · $8.6M priced

What the filings say about GH

Insiders, 180 days
-$122.5M net sold
1 buyer · 15 sellers · 5% of sales under a 10b5-1 plan
Congress, 1 year
1 bought · 0 sold
Latest: purchase, 2026-09-28
Planned sales (Form 144), 90 days
$32.5M
14 notices

Guardant Health insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Guardant Health, Inc. insiders sold a net $122.5M of stock across 240 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
Tariq Musa
Director
SELL
2026-10-19 SECtraded 2026-10-16
116
$19.2K
+4.0%
Context
  • 22 earlier Form 4 trades (code P or S) here by this insider (22 sales), the last on Sep 16, 2026.
  • The trade is 1.0% of the 11,583 shares held after it.
  • 2 other insiders sold within 30 days.
  • 365 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Tariq Musa sold about $19.2K of GH under a 10b5-1 plan on Oct 16, 2026; 2 other insiders sold within 30 days and 365 funds added in the latest 13F quarter.
Azar Alex M II
Director
SELL
2026-10-15 SECtraded 2026-10-14
69
$11.0K
+6.6%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Sep 16, 2026.
  • The trade is 7.7% of the 893 shares held after it.
  • 3 other insiders sold within 30 days.
  • 365 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Azar Alex M II sold about $11.0K of GH under a 10b5-1 plan on Oct 14, 2026; 3 other insiders sold within 30 days and 365 funds added in the latest 13F quarter.
Tariq Musa
Director
SELL
2026-09-17 SECtraded 2026-09-16
116
$20.3K
-5.7%
Context
  • 21 earlier Form 4 trades (code P or S) here by this insider (21 sales), the last on Aug 17, 2026.
  • The trade is 1.0% of the 11,449 shares held after it.
  • 5 other insiders sold within 30 days.
  • 365 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Tariq Musa sold about $20.3K of GH under a 10b5-1 plan on Sep 16, 2026; 5 other insiders sold within 30 days and 365 funds added in the latest 13F quarter.
Krognes Steve E.
Director
SELL
2026-09-17 SECtraded 2026-09-16
1,103
$192.4K
-5.7%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Jun 4, 2026.
  • The trade is 8.2% of the 13,477 shares held after it.
  • 5 other insiders sold within 30 days.
  • 365 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Krognes Steve E. sold about $192.4K of GH on Sep 16, 2026; 5 other insiders sold within 30 days and 365 funds added in the latest 13F quarter.
Krognes Steve E.
Director
SELL
2026-09-17 SECtraded 2026-09-16
3,300
$578.9K
-5.7%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Jun 4, 2026.
  • The trade is 32.4% of the 10,177 shares held after it.
  • 5 other insiders sold within 30 days.
  • 365 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Krognes Steve E. sold about $578.9K of GH on Sep 16, 2026; 5 other insiders sold within 30 days and 365 funds added in the latest 13F quarter.
240 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 235 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$122.5M over 180 days
-$30.7M over 90 days
below 87% of Healthcare Services
Congress
1 member bought in the last year
the lowest in Healthcare Services
Funds
365 funds bought in last quarter
more than 93% of Healthcare Services
Revenue
+32.9% year over year
more than 81% of Healthcare Services
Margin
-42.4% net margin
below 87% of Healthcare Services
Buybacks
$45.0M repurchased, FY to 2025-12-31
below 55% of Healthcare Services
Short interest
9.2% of the float short (float per yahoo 2026-10-26) · 6.2 days to cover · settled 2026-09-30
more than 84% of Healthcare Services
What changed in the last 30 days
Oct 19Rep. Jonathan Jackson sold $15K to $50K, disclosed 21 days after the trade
Why it matters
House members report a bracket, not an exact amount, and have 45 days to do it; the trade is weeks old when it becomes public.
Oct 19Director Tariq Musa sold $19.2K under a 10b5-1 plan (Oct 16)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 16Director Tariq Musa filed to sell $19.2K by Oct 16 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Oct 15Director Azar Alex M II sold $11.0K under a 10b5-1 plan (Oct 14)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 14Director Azar Alex M II filed to sell $11.0K by Oct 14 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.

Watch GH

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+148.5%12M
+0%+58%+117%+175%2025-102025-122026-022026-042026-062026-082026-10 2026-06-29 · Talasaz AmirAli sold $10.7M2026-06-26 · Talasaz AmirAli sold $9.6M2025-12-15 · Eltoukhy Helmy sold $8.7M2026-06-26 · Talasaz AmirAli sold $8.0M2026-06-29 · Talasaz AmirAli sold $7.1M2026-06-05 · Eltoukhy Helmy sold $6.2M2026-08-10 · Freeman Chris sold $6.0M2026-05-12 · Talasaz AmirAli sold $5.0M2026-06-05 · Eltoukhy Helmy sold $4.3M2026-05-20 · Talasaz AmirAli sold $4.2M2026-05-20 · Talasaz AmirAli sold $4.1M2026-06-29 · Talasaz AmirAli sold $3.9M2026-05-20 · Talasaz AmirAli sold $3.6M2026-08-21 · Talasaz AmirAli sold $3.5M2025-12-08 · Talasaz AmirAli sold $3.2M2026-05-20 · Talasaz AmirAli sold $3.2M2026-08-12 · Monroe Terilyn J. sold $3.1M2026-05-20 · Talasaz AmirAli sold $3.0M2026-08-10 · Freeman Chris sold $3.0M2026-05-22 · Freeman Chris sold $2.9M2026-03-04 · Kalia Kumud sold $2.6M2025-12-01 · Monroe Terilyn J. sold $2.5M2025-12-05 · Bell Michael Brian sold $2.3M2026-05-20 · Talasaz AmirAli sold $2.3M2026-08-12 · Monroe Terilyn J. sold $2.2M2025-12-01 · Monroe Terilyn J. sold $2.0M2025-12-05 · CLARK IAN T sold $1.8M2026-06-05 · Eltoukhy Helmy sold $1.8M2026-08-12 · Monroe Terilyn J. sold $1.6M2025-12-08 · Talasaz AmirAli sold $1.6M2026-08-21 · Talasaz AmirAli sold $1.5M2026-08-04 · CLARK IAN T sold $1.4M2025-12-08 · Chudova Darya sold $1.4M2026-09-15 · Chudova Darya sold $1.4M2026-08-21 · Talasaz AmirAli sold $1.3M2026-05-20 · Talasaz AmirAli sold $1.3M2026-05-27 · Saia John G. sold $1.3M2026-03-04 · Kalia Kumud sold $1.2M2025-12-05 · Bell Michael Brian sold $1.2M2026-08-10 · Freeman Chris sold $1.2M2026-06-04 · Krognes Steve E. sold $1.2M2025-12-05 · Freeman Chris sold $1.2M2026-10-16 · Tariq Musa filed to sell $19.2K2026-10-14 · Azar Alex M II filed to sell $11.0K2026-09-16 · Azar Alex M II filed to sell $144.6K2026-09-16 · Krognes Steve E. filed to sell $1.2M2026-09-16 · Tariq Musa filed to sell $20.3K2026-09-15 · Chudova Darya filed to sell $1.4M2026-09-11 · Kalia Kumud filed to sell $632.2K2026-08-21 · Talasaz AmirAli filed to sell $6.3M2026-08-17 · Tariq Musa filed to sell $18.1K2026-08-12 · Monroe Terilyn J. filed to sell $7.6M2026-08-10 · Freeman Chris filed to sell $10.8M2026-08-05 · Joyce Meghan V. filed to sell $1.8M2026-08-05 · Hidalgo Medina Manuel filed to sell $279.2K2026-08-04 · CLARK IAN T filed to sell $2.3M2026-07-16 · Tariq Musa filed to sell $18.9K2026-07-01 · Joyce Meghan V. filed to sell $660.0K2026-06-26 · Joyce Meghan V. filed to sell $300.1K2026-06-26 · Talasaz AmirAli filed to sell $39.2M2026-06-24 · Joyce Meghan V. filed to sell $280.0K2026-06-22 · Joyce Meghan V. filed to sell $812.6K
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns GH: institutional holders (13F)

13F holdings, latest reported quarter
BlackRock, Inc.
7,622,935 sh
$1.1B
VANGUARD CAPITAL MANAGEMENT LLC
5,755,857 sh
$863.6M
FMR LLC
5,488,272 sh
$823.4M
VANGUARD PORTFOLIO MANAGEMENT LLC
5,445,785 sh
$817.0M
Invesco Ltd.
4,429,755 sh
$664.6M

Congress trades in GH

STOCK Act disclosures, US House only, filed up to 45 days after the trade
Jonathan Jackson
Bought 2026-09-28 · disclosed 21 days later
$15,001 - $50,000
All stocks members of Congress are buying · Every member's trades

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

GH planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Tariq Musa
Filed 2026-10-16
$19.2K
Azar Alex M II
Filed 2026-10-14
$11.0K
Azar Alex M II
Filed 2026-09-16
$144.6K
Krognes Steve E.
Filed 2026-09-16
$1.2M
Tariq Musa
Filed 2026-09-16
$20.3K

GH mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Franklin Genomic Advancements ETF
$2.5M position · as of 2026-06-30
9.1%
Global X Genomics & Biotechnology ETF
$3.1M position · as of 2026-05-31
5.6%
Eventide Gilead Fund
$189.8M position · as of 2026-06-30
5.5%
F/m Emerald Life Sciences Innovation ETF
$5.8M position · as of 2026-05-31
5.5%
Eventide Healthcare & Life Sciences Fund
$96.1M position · as of 2026-06-30
5.4%
Goldman Sachs Future Health Care Equity ETF
$1.1M position · as of 2026-05-31
5.3%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
6 registered trials, 6 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
6
Not applicable
6 active
What changed recently
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
2026-09-15 · Completion moved 2029-08 → 2030-08
,
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Executive pay vs shareholder return · Helmy Eltoukhy
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2020
$113.9M
$196.4M
$29.8M
+65%
+26%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $122.5M sold by insiders over 180 days, 365 funds added last quarter, 1 House member(s) bought in 12 months, disclosed weeks after the trade, $32.5M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
NTRACSTLPGNYHIMSWGSPRVATDOCAVAHADUSSERABDSXBLLN

GH financials

Revenue growth
+32.9%
XBRL, annual
Net margin
-42.4%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$1.2B
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-38.3%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$240.7M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Cash flow to debt
-0.12x
TTM operating cash flow over long-term debt only, 2026-06-30
Return on equity
n/a
average equity is zero or negative
Return on assets
-28.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-35.3%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$23.1B
market value at close 2026-10-23 on 2026-07-24 shares, plus long-term debt only, 2026-06-30, minus cash 2026-06-30
FCF yield
-1.1%
TTM free cash flow over market value at close 2026-10-23
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$982.0M$739.0M$563.9M$449.5M
Operating income-$437.2M-$443.6M-$564.7M-$544.4M
Net income-$416.3M-$436.4M-$479.4M-$654.6M
EPS (diluted)-3.32-3.56-4.28-6.41
Operating cash flow-$184.8M-$239.9M-$325.0M-$309.5M
Cash$378.2M$525.5M$1.1B$141.6M
Long-term debt$1.5B$1.1B$1.1B$1.1B
Buybacks$45.0M$0$0n/a
SEC XBRL, fiscal years, as known on 2026-10-27

GH Stock Sonar score 6/7 axes

Find similar shapesCompare

GH ranks highest on institutional and government (83rd percentile) and growth (81st), and lowest on profitability (23rd), among Healthcare Services peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
23
Inputs
  • Return on equityaverage equity is zero or negative
  • Return on assets-28.0% · 29 pct, sector of 88
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-35.3% · 16 pct, sector of 68
Financial health
34
Inputs
  • Debt to equityequity is zero or negative, the ratio has no meaning
  • Cash flow to debt-0.12x · 34 pct, sector of 66
Growth
81
Inputs
  • Revenue growth, YoY+32.9% · 81 pct, sector of 87
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
37
Inputs
  • Net Form 4 buying (codes P and S), 180d-$122.3M · 11 pct, sector of 64
  • Insider buyers, 180d1 · 63 pct, sector of 64
Institutional and government
83
Inputs
  • Funds adding, latest quarter365 · 93 pct, sector of 73
  • Congress net buyers, 365d1 · 73 pct, universe of 719
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quarters$2.2M · 83 pct, universe of 1,063
Risk and compliance
61
Inputs
  • Short interest, % of float+9.2% · 29 pct, sector of 95
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+3.1% · 93 pct, sector of 72
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

GH filings, in plain words

Are Guardant Health insiders buying or selling GH?

In the 180 days to 2026-10-27, Guardant Health insiders were net sellers, a net $122.5M: $78.5K of purchases and $122.5M of sales reported on Form 4, by 1 buyer and 15 sellers.

Have members of Congress traded GH?

Yes. In the year to 2026-10-27, 1 House member disclosed buying GH and 0 House members disclosed selling it; the latest on record is a purchase by Jonathan Jackson dated 2026-09-28.

Are there planned insider sales of GH?

Yes. 14 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $32.5M of stock; the latest, by Tariq Musa, was filed 2026-10-16.

Read the full summary

In the 180 days to 2026-10-27, Guardant Health insiders were net sellers of GH, a net $122.5M across purchases and sales reported on Form 4 by 1 buyer and 15 sellers. Sales outweighed purchases more than tenfold by value. 5% of the 78 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. In the year to 2026-10-27, 1 member of Congress disclosed buying GH and 0 members disclosed selling it; the latest on record is a purchase by Jonathan Jackson dated 2026-09-28. Insiders filed 14 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $32.5M of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies